LENZ Therapeutics Inc

LENZ is in a Stage 4 decline with persistent lower highs and lower lows under down-sloping EMAs, confirming bearish structure across both medium and long terms. Short-term execution timing is neutral as price tightly tracks below declining EMAs amid extreme oversold readings, offering no clear entry. With a speculative strategy requiring high selectivity, execution is deferred and best considered on any rally into EMA resistance.

• ↑Q1 revenue $1.9M from ~25K VIZ prescriptions, 19% QoQ growth
• ↑Telehealth prescribing option launched for direct home delivery access
• ↓Q1 net loss $41.5M exceeded revenue; SG&A set to total $80–100M